TY - JOUR
KW - Albuminuria/complications
KW - Bilirubin
KW - *Diabetes Mellitus
KW - *Diabetes Mellitus, Type 2
KW - Disease Progression
KW - Glomerular Filtration Rate
KW - Humans
KW - Kidney
KW - *Renal Insufficiency, Chronic
KW - Risk Factors
AU - Y. Aoki
AU - C. Cabrera
AU - M. Ouwens
AU - K. Bamberg
AU - J. Nyström
AU - I. Raz
AU - B. Scirica
AU - B. Hamrén
AU - P. Greasley
AU - D. Rekić
AD - Clinical Pharmacology and Safety Sciences, AstraZeneca, Gothenburg, Sweden.
Real World Science and Digital, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
Biometrics Oncology, AstraZeneca, Gothenburg, Sweden.
Early Clinical Development, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM) BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Hadassah University Hospital, Jerusalem, Israel.
Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts, United States of America.
Harvard Medical School, Boston, Massachusetts, United States of America.
AN - 35727760
BT - PLoS One
C2 - PMC9212140
DO - 10.1371/journal.pone.0269970
DP - NLM
ET - 2022/06/22
LA - eng
M1 - 6
N1 - 1932-6203
Aoki, Yasunori
Orcid: 0000-0002-5881-2023
Cabrera, Claudia S
Ouwens, Mario
Bamberg, Krister
Nyström, Jenny
Raz, Itamar
Scirica, Benjamin M
Hamrén, Bengt
Greasley, Peter J
Orcid: 0000-0002-2529-4477
Rekić, Dinko
Orcid: 0000-0002-5310-8002
Journal Article
Randomized Controlled Trial
PLoS One. 2022 Jun 21;17(6):e0269970. doi: 10.1371/journal.pone.0269970. eCollection 2022.
PY - 2022
SN - 1932-6203
EP - e0269970
T2 - PLoS One
TI - Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data
VL - 17
ER -